NuoGene Bio Completes Tens of Millions RMB Pre-A Financing to Advance In Situ Transdifferentiation-Based Gene Therapies

Investment界 (ID: pedaily2012) News, NEUREGEN announced in December 2023 the completion ofTens of Millions of Yuan in Pre-A Round Financing. This round of financing was led byUpShanghai Science & Technology Investment Co. Ltd led the investment, with Wuhan Baiwin, Shanghai Sinan Park Science, and Shanghai Biomedical Public Technology Service Co. Ltd participating.Other institutions followed suit with additional investments, and the founding shareholders of NEUREGEN (including the core team) also strategically increased their investment. This round of financing will be used to further accelerate the company's R&D progress and team building efforts.

In situ transdifferentiation is a new generation of cell reprogramming technology iteratively developed from the Nobel Prize-winning iPSC technology, marking a significant milestone breakthrough in the field of regenerative medicine. NEUREGEN is a biotechnology company aiming to develop novel gene therapy drugs by utilizing its proprietary in situ transdifferentiation technology.

NEUREGEN was co-founded by a pioneering team in the field of in situ transdifferentiation technology and seasoned experts from the gene therapy industry. The core team members come from renowned institutions such as the Chinese Academy of Sciences, Peking Union Medical College, University of California San Francisco, University of Florida, and UT Southwestern Medical Center, among other prestigious universities and well-known companies worldwide. The team possesses cutting-edge in situ transdifferentiation technology and translational experience, as well as invaluable expertise in successfully managing the entire drug development lifecycle.

Centering on the cell in-situ transdifferentiation technology, NEUREGEN has established a key R&D platform for novel gene therapy drugs, including core technologies such as screening of transdifferentiation factors, design of viral and non-viral vectors, and development of in vivo and in vitro pharmacodynamic methods. The company has also applied for several critical patents both in China and internationally.

Currently, NEUREGEN's product pipeline focuses on neurological diseases, primarily targeting blinding eye conditions and difficult-to-treat nervous system tumors by developing original gene therapy drugs with independent intellectual property rights. It is rapidly expanding into major neurodegenerative diseases. In the future, there is significant potential to broaden into wider areas such as regenerative therapies, cancer treatments, and the emerging field of anti-aging.

The pipelines for primary glioma and retinal degenerative diseases have both obtained reliable support from animal experimental data and are about to enter the investigator-initiated clinical stage. Subsequent multiple pipelines will also gradually move into the preclinical research and development phase. Based on NEUREGEN's unique platform technology for treating various neurological disorders, a series of unmet clinical needs can be effectively addressed, bringing new therapeutic hope to a wide range of patients.

Dr. Zhu Chao, Co-Founder, Chairman and Chief Executive Officer of NEUREGENExpressed: Thanks to the current round of investors for their high recognition of NEUREGEN's team and core technology platform, as well as their strong support for truly original innovative technologies! Based on the advantages of large-scale screening and optimization of highly efficient transdifferentiation factors and an original recombinant viral vector platform, NEUREGEN, with its globally novel neurogenic in-situ transdifferentiation technology, is developing a universal gene therapy for neurological tumors, injuries, degenerative diseases, and anti-aging by closely aligning with unmet clinical needs and leveraging its own technical characteristics. NEUREGEN will live up to its mission, continuously expand its technological advantages, rapidly advance its R&D pipeline, and contribute to bringing innovative gene therapies to patients as soon as possible.

Wu Jie, Vice General Manager of Shanghai Science & Technology Investment Co. LtdIn-situ transdifferentiation is an important development direction for gene therapy, and has achieved phased results in some indications, showing great application prospects. We value the platform value of NEUREGEN, as well as the scientific research capabilities of its core team and their valuable experience in advancing new drug R&D and industrialization. In the current capital environment, investors are becoming more cautious about investing in innovative drugs. We hope to return to unmet clinical "real needs" and make meaningful investments. NEUREGEN is a pragmatic team, and we look forward to the company's pipeline bringing new treatment hopes to patients as soon as possible.

Wuhan Baiying Bio-Industry Investment Management Co., Ltd.NEUREGEN has a solid foundation of underlying technology and rich experience in industrialization. The company also has significant advantages in cutting-edge technology innovation and clinical value. We are optimistic about the company's potential and value in the field of in-situ transdifferentiation. Baiwin Biotech has long been dedicated to investing in the biomedicine and health sector. This collaboration reflects our consistent commitment to supporting early-stage and original innovation projects. Moving forward, we will continue to support the company’s development, believing that its platform technology can bring better innovative therapies to patients as soon as possible.

UpQu JiPing, Investment Director of Haisi Nan Yuan Private Fund Management Co., Ltd.NEUREGEN's self-developed in-situ transdifferentiation technology represents a new generation of cell reprogramming technology, offering innovative solutions and methods for numerous unmet clinical needs. NEUREGEN applies this technology to two key areas: oncology and neural regeneration and repair, where the clinical demand is clear, presenting significant market value and development potential. Sinan Park Capital acknowledges the efforts and expertise accumulated by Dr. Zhu Chao and his team in this field, and looks forward to NEUREGEN accelerating its pipeline progress to bring products to market as soon as possible for the benefit of patients both in China and internationally. Sinan Park Capital, a private equity fund manager under Shanghai Lingang Group that focuses on early-stage technology startups, targets cutting-edge scientific domains, fostering innovation enterprises around promising sectors with long-term growth prospects to build an industrial innovation ecosystem. This investment in NEUREGEN by a fund under Sinan Park Capital marks a strategic move into the field of CGT regenerative medicine and novel therapies.

Li Jizong, Chairman of Shanghai Biomedical Public Technology Service Co., Ltd.NEUREGEN Shows Significant Advantages in Neural In-situ Transdifferentiation Innovative Gene Therapy. The essence of the biopharmaceutical industry is to originate from clinical needs, return to clinical applications, and benefit the public. Under the supervision and guidance of the Shanghai Biomedical Technology Development Center, Shanghai Science & Technology Investment Co. Ltd adheres to the philosophy of "investing early, investing small, and investing in hard technology." It consistently focuses on cutting-edge biopharmaceutical technologies, strengthens forward-looking investment strategies, fully supports the transformation of biopharmaceutical scientific and technological innovations, promotes the market entry of innovative products with genuine clinical value, and benefits public health.

Dr. Wang Xiaoyan, Partner of Jinsha River United Runpu Medical Fund, Angel InvestorComment: The in-situ transdifferentiation technology provides a breakthrough potential treatment for neurological diseases. Since its establishment, NEUREGEN has continued to make solid business progress, and its future is promising. We will continue to empower and support the development of NEUREGEN, and look forward to the company’s platform technology moving into clinical applications as soon as possible to benefit a large number of patients.